|Podcasts|November 3, 2017

Alzheimer Disease: New Drugs in the Offing?

What medications are in the pipeline that may help slow or even prevent the development of Alzheimer disease?

Here, Howard Fillit, MD, Founding Executive Director and Chief Science Officer of the Alzheimer's Drug Discovery Foundation, talks briefly about the most promising drugs-and the role of the ADDF in helping to bring those drugs through clinical trials.

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Subscribe Now!

Latest CME

Video

Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice

Paul G. Auwaerter, MD, MBA; Paul P. Doghramji, MD, FAAFP; Aruna Subramanian, MD

Alzheimer Disease: New Drugs in the Offing?

Newsletter

Related Content

Efgartigimod Effective in Seronegative gMG, Obexelimab Meets Primary End Point, FDA Accepts NDA for Tau Tracer MK-6240

Episode 153: Overviewing the 2025 Alzheimer's Association's Blood-Based Biomarker Guidelines

FDA Accepts New Drug Application for Tau PET Imaging Agent MK-6240 in Alzheimer Disease

Benzodiazepines and Antipsychotics Tied to Higher Mortality in Hospice Patients With Dementia

FDA Fast Tracks Etalanetug, Encouraging Interim TEMPO-4 Data, Initial Data on Cell Therapy UX-DA001

Latest CME

Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Patient, Provider, and Caregiver Connection™: Pediatric Myasthenia Gravis—Current Treatment and Emerging Concepts

Mind Moments™: Optimizing Management for Patients with Generalized Myasthenia Gravis

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

Identifying and Treating CIDP in the Modern Era

Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Designing the Phase 3 EMPEROR Trial and Future Considerations

NeurologyLive® Friday 5 — October 31, 2025

Evaluating Combined Supraorbital and Occipital Neuromodulation in Phase 3 Trial for Resistant Migraine: The RECLAIM Study

AI in MS: IJMSC Survey Results

Efgartigimod Effective in Seronegative gMG, Obexelimab Meets Primary End Point, FDA Accepts NDA for Tau Tracer MK-6240